Type 2 Diabetes Mellitus Increases the Risk for Developing Monoclonal Gammopathy of Undetermined Significance in Asian Populations
Authors: Chang Su-Hsin , Wang Mei , Chen Pin-Xiang , Hsu Sylvia H , Hu Ming-Che , Wei Chia-Cheng 
Published: December 2024

Background: Epidemiological studies have shown inconsistent evidence of the association between type 2 diabetes mellitus (T2DM) and lymphoproliferative disorders, including monoclonal gammopathy of undetermined significance (MGUS), the most common plasma cell disorder. MGUS is also a premalignant condition of multiple myeloma, Waldenström macroglobulinemia, light-chain amyloidosis, or related conditions. Studies have shown that the association between T2DM and MGUS may be explained by insulin resistance and chronic inflammation via inflammatory cytokines, tumor necrosis factor alpha, and interleukin-1β. However, this association may be attenuated by the use of T2DM medications. This association is further perplexed by well-established racial differences in the prevalence and incidence of T2DM and MGUS, with a higher percentage of Black populations inflicted with the two diseases than their White counterparts. It is however unclear whether the association holds in Asian populations, as these populations are understudied. The goal of this study was to examine whether T2DM increased the risk for MGUS in Asian populations.

Methods: We used data from Taiwan National Health Insurance databases. Taiwan National Health Insurance is a national health insurance system introduced in 1995. As the enrollment is mandatory, 99% of the citizens (&gt;95% are Asians) are enrolled. We identified patients diagnosed with T2DM from 2001-2021. The outcome was time from age 16 (baseline) to MGUS diagnosis, if any. The association between T2DM and MGUS was estimated by a multivariable-adjusted hazard ratio (aHR) using the Fine-Gray distribution hazard model with death as a competing event and incident T2DM as time-varying exposure. The covariates included age at incident T2DM, gender, and Charlson Comorbidity Index (CCI) at baseline.

Results: This study included 3,195,750 individuals who had incident T2DM between 2001 and 2021. Among them, 53.7% were female, mean CCI was 0.01 (standard deviation, std, 0.14), 1,620 (0.05%) developed MGUS with a median follow-up of 51 (interquartile range, 41-60) years. The mean age at incident T2DM was 57 (std 14) years and the mean age at MGUS was 70 (std 12) years. In the multivariable analysis, T2DM increased the risk for MGUS (aHR: 2.33, 95% confidence interval, CI: 1.93-2.81, p &lt;0.0001). In addition, male sex (aHR: 1.21, 95% CI: 1.09-1.33, p =0.0002) and higher CCI (aHR: 1.45, 95% CI: 1.06-1.99, p =0.0221) were independently associated with higher risk for MGUS. Older age at incident T2DM was negatively associated with the risk for MGUS (aHR: 0.990, 95% CI: 0.985-0.995, p &lt;0.0001).

Conclusions and Relevance: In Taiwan, with populations predominantly Asian, T2DM increases the risk for developing MGUS by 133% and the risk for MGUS decreases by age at incident T2DM. More studies in other Asian countries are needed to confirm the generalizability of a positive association between T2DM and MGUS in Asian populations.